MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Celldex Therapeutics Long Term Debt Current 2011-2026 | CLDX
Annual Long Term Debt Current Celldex Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.45 M | 1.61 M | 1.44 M | 1.75 M | 1.33 M | 1.94 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 M | 1.33 M | 1.59 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
86.4 M | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
1.18 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
39.5 M | $ 117.62 | 1.41 % | $ 27.2 B | Germany |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 11.66 | -8.95 % | $ 768 M | USA |
 |
BioXcel Therapeutics
BTAI
|
374 K | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
BioLineRx Ltd.
BLRX
|
522 K | $ 3.12 | 0.59 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Cellectis S.A.
CLLS
|
8.38 M | $ 4.13 | -6.56 % | $ 116 M |  France |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 233.49 | -0.81 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
768 K | $ 2.04 | -2.39 % | $ 183 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
1.42 M | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
224 M | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
339 M | $ 94.24 | 1.38 % | $ 96.9 B | Britain |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |